V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
N
NKTRAI Stock Diagnostic Report

Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute over Rezpeg

Nektar Therapeutics shares fell ahead of the ruling in its Rezpeg patent dispute with Eli Lilly.

View Source Article ↗
AI CATALYST SCORE45 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

NKTR Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-10-12 18:38:43NKTR65MidView Report →
2026-09-25 11:31:36NKTR70MidView Report →
2026-09-22 19:21:34NKTR45MidView Report →
View Full History for NKTR (Blueprint) →